Literature DB >> 27136433

How we treat bleeding associated with direct oral anticoagulants.

Giuseppe Marano1, Stefania Vaglio1, Simonetta Pupella1, Giancarlo M Liumbruno1, Massimo Franchini2.   

Abstract

Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the case of bleeding or emergency situations such as trauma, stroke requiring thrombolysis, and urgent surgery. The progressive development of antidotes for these new drugs, which, it is hoped, will become available in the near future, will allow better and safer management of the rapid reversal of their anticoagulant effect.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27136433      PMCID: PMC5016308          DOI: 10.2450/2016.0180-15

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  81 in total

Review 1.  New direct oral anticoagulants--current therapeutic options and treatment recommendations for bleeding complications.

Authors:  Wolfgang Miesbach; Erhard Seifried
Journal:  Thromb Haemost       Date:  2012-07-10       Impact factor: 5.249

Review 2.  Reversal of anticoagulants: an overview of current developments.

Authors:  Andreas Greinacher; Thomas Thiele; Kathleen Selleng
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

Review 3.  Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.

Authors:  Andres Enriquez; Gregory Y H Lip; Adrian Baranchuk
Journal:  Europace       Date:  2015-03-26       Impact factor: 5.214

4.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Authors:  Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

5.  Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

Authors:  Anne Godier; Anastasia Miclot; Bernard Le Bonniec; Marion Durand; Anne-Marie Fischer; Joseph Emmerich; Catherine Marchand-Leroux; Thomas Lecompte; Charles-Marc Samama
Journal:  Anesthesiology       Date:  2012-01       Impact factor: 7.892

6.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

Review 7.  Pulmonary embolism and deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Henri Bounameaux
Journal:  Lancet       Date:  2012-04-10       Impact factor: 79.321

8.  Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

Authors:  Wei Zhou; Sönke Schwarting; Sergio Illanes; Arthur Liesz; Moritz Middelhoff; Markus Zorn; Martin Bendszus; Sabine Heiland; Joanne van Ryn; Roland Veltkamp
Journal:  Stroke       Date:  2011-10-13       Impact factor: 7.914

9.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

View more
  5 in total

1.  The Italian Regulatory Guidelines for the implementation of Patient Blood Management.

Authors:  Stefania Vaglio; Sara Gentili; Giuseppe Marano; Simonetta Pupella; Daniela Rafanelli; Gianni Biancofiore; Paola Antonioli; Claudio Velati; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2017-05-03       Impact factor: 3.443

Review 2.  A review of guidelines on anticoagulation reversal across different clinical scenarios - Is there a general consensus?

Authors:  Truman J Milling; Charles V Pollack
Journal:  Am J Emerg Med       Date:  2020-05-28       Impact factor: 4.093

Review 3.  An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents.

Authors:  Amir Sadeghi; Mohammad Reza Zali; Hamid Mohaghegh Shalmani; Pardis Ketabi Moghadam; Mohsen Rajabnia Chenari; Mohammad Ali Karimi; Sina Salari; Hamid Asadzadeh-Aghdaei
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

Review 4.  Management of Coagulopathy in Bleeding Patients.

Authors:  Stefan Hofer; Christoph J Schlimp; Sebastian Casu; Elisavet Grouzi
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

5.  Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.

Authors:  Dagmar Kubitza; Michael Heckmann; Jana Distler; Annemone Koechel; Stephan Schwers; Friederike Kanefendt
Journal:  Br J Clin Pharmacol       Date:  2022-03-24       Impact factor: 3.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.